Metin Kurtoglu

Metin Kurtoglu

Company: Cartesian Therapeutics

Job title: Chief Operating Officer


Seminar: RNA Cell Therapy: In & Beyond Oncology

  • Engineering cells ex vivo with RNA combines the best attributes of conventional RNA-based therapeutics and conventional DNA-engineered cells
  • Cell products engineered with RNA that expresses Chimeric Antigen Receptor (CAR) is already being tested for autoimmune disease and frontline oncology indications
  • RNA Cell Therapies have a much bigger potential than just safe CAR-T therapies: A highly innovative feature of RNA Cell Therapy is that there is no cargo limit so cells can
    be transfected with multiple RNAs to arm the cell with multiple therapeutic functions

Day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.